

Munich Cancer Registry



- ▶ Incidence and Mortality
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

ICD-10 C16: Stomach cancer

Survival

Year of diagnosis	1988-1997	1998-2016
Patients	2,572	14,047
Diseases	2,574	14,087
Cases evaluated	2,299	10,441
Creation date	08/22/2018	
Export date	08/09/2018	
Population	4.81 m	



Munich Cancer Registry
Cancer Registry Bavaria - Upper Bavaria Regional Center
at Klinikum Grosshadern/IBE
Marchioninstr. 15
Munich, 81377
Germany

<https://www.tumorregister-muenchen.de/en>

https://www.tumorregister-muenchen.de/en/facts/surv/sC16__E-ICD-10-C16-Stomach-cancer-survival.pdf

Index of figures and tables

Fig./Tbl.		Page
1a	Relative survival by period of diagnosis (chart)	3
1b	Survival by period of diagnosis (table)	3
2a	Survival by sex (chart)	4
2b	Survival by sex (table)	4
3a	Observed survival by age category (chart)	5
3b	Relative survival by age category (chart)	5
3c	Survival by age category (table)	6
4a	Relative survival by UICC 1988+ (chart)	7
4b	Survival by UICC 1988+ (table)	7
4c	Relative survival by UICC 1998+ (chart)	8
4d	Survival by UICC 1998+ (table)	8
4e	Relative survival by TNM staging 1988+ (chart)	9
4f	Survival by TNM staging 1988+ (table)	9
4g	Relative survival by TNM staging 1998+ (chart)	11
4h	Survival by TNM staging 1998+ (table)	11
4i	Conditional survival by extent of disease (chart)	13
4j	Conditional survival by extent of disease (table)	13
5a	Time to first progression (chart)	14
5b	Time to first progression (table)	14
5c	Observed post-progression survival (chart)	16
5d	Observed post-progression survival (table)	16
5e	Observed post-progression survival by period of progression (chart)	17
5f	Observed post-progression survival by period of progression (table)	17




Figure 1a. Relative survival of patients with stomach cancer by period of diagnosis. Included in the evaluation are 12,262 cases diagnosed between 1988 and 2016.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2000 to 2014, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Years	Period of diagnosis					
	1988-1997 n=2,295		1998-2006 n=4,513		2007+ n=5,454	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	62.5	64.9	56.3	58.9	61.4	63.9
2	48.8	52.5	42.8	46.4	46.8	50.2
3	41.9	46.6	35.9	40.3	40.4	44.7
4	38.0	43.6	31.9	37.0	36.4	41.5
5	34.9	41.4	28.8	34.7	33.5	39.4
6	32.4	39.6	26.9	33.5	31.7	38.6
7	30.2	38.1	24.7	31.8	30.3	38.1
8	28.1	36.6	22.9	30.6	29.1	38.0
9	26.4	35.6	21.1	29.2		
10	25.2	35.1	19.5	27.9		
11	23.7	34.0	18.4	27.3		
12	22.0	32.6	17.1	26.3		
13	20.3	31.1	15.9	25.4		
14	18.9	29.9	14.9	24.5		
15	17.4	28.4	13.9	23.8		

Table 1b. Observed (obs.) and relative (rel.) survival of patients with stomach cancer by period of diagnosis for period 1988-2016 (N=12,262).




Figure 2a. Survival of patients with stomach cancer by sex. Included in the evaluation are 9,967 cases diagnosed between 1998 and 2016.

Years	Sex			
	Male n=5,705		Female n=4,262	
	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	60.6	63.2	56.9	59.4
2	45.6	49.1	44.1	47.5
3	38.5	42.9	37.9	42.2
4	34.4	39.6	33.9	39.0
5	31.1	37.1	31.2	37.0
6	28.9	35.7	29.5	36.2
7	26.6	34.1	27.7	35.2
8	24.9	33.0	26.0	34.0
9	22.9	31.5	24.1	32.7
10	21.3	30.3	22.2	31.2
11	19.9	29.4	21.1	30.6
12	18.7	28.7	19.4	29.0
13	17.3	27.4	18.2	28.3
14	16.2	26.6	17.0	27.3
15	15.0	25.7	16.0	26.5

Table 2b. Observed (obs.) and relative (rel.) survival of patients with stomach cancer by sex for period 1998-2016 (N=9,967).




Figure 3a. Observed survival of patients with stomach cancer by age category. Included in the evaluation are 12,262 cases diagnosed between 1988 and 2016.




Figure 3b. Relative survival of patients with stomach cancer by age category. Included in the evaluation are 12,262 cases diagnosed between 1988 and 2016.

Years	Age category									
	0-49 yrs n=1,032		50-59 yrs n=1,773		60-69 yrs n=2,828		70-79 yrs n=3,739		80+ yrs n=2,890	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	74.9	75.0	73.1	73.5	68.1	69.1	58.2	60.4	39.7	44.6
2	60.0	60.0	58.6	59.4	53.3	54.9	44.4	47.8	27.1	34.0
3	52.4	52.6	51.7	52.8	47.0	49.2	37.5	42.1	20.7	29.2
4	48.9	49.2	47.9	49.2	42.2	45.0	33.5	39.3	17.3	27.5
5	46.4	47.0	44.7	46.3	39.6	43.1	29.8	36.8	14.6	26.5
6	44.2	44.7	42.5	44.5	37.6	41.8	27.6	36.0	12.6	26.4
7	42.2	42.9	40.8	43.1	35.8	40.7	25.1	34.8	10.6	25.9
8	40.4	41.2	40.1	42.8	34.1	39.7	22.7	33.6	8.7	25.0
9	39.8	40.8	38.8	41.8	32.7	39.2	20.2	32.1	6.5	22.4
10	38.7	39.9	37.3	40.7	31.7	39.0	18.3	31.4	4.7	20.2
11	37.7	39.0	35.9	39.6	30.3	38.4	16.7	31.3	3.7	19.6
12	37.5	38.9	34.2	38.3	28.2	37.1	14.5	29.8	3.1	20.3
13	36.3	38.0	33.0	37.5	27.2	37.0	12.2	27.8		
14	35.4	37.1	31.9	36.8	25.6	36.2	10.5	26.5		
15	35.0	36.7	30.8	36.3	23.4	34.8	8.6	24.4		

Table 3c. Observed (obs.) and relative (rel.) survival of patients with stomach cancer by age category for period 1988-2016 (N=12,262).




Figure 4a. Relative survival of patients with stomach cancer by UICC. For 10,073 of 12,262 cases diagnosed between 1988 and 2016 valid data could be obtained for this item. For a total of 8,705 cases an evaluable classification was established. The grey line represents the subgroup of 3,557 patients with missing values regarding UICC (29.0 % of 12,262 patients, the percent values of all other categories are related to n=8,705).

Years	UICC													
	IA n=1,632		IB n=1,152		II n=1,587		IIIA n=951		IIIB n=53		IV n=3,330		NA/NOS n=3,557	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	90.6	93.5	87.3	90.6	78.2	81.0	59.5	62.1			31.3	32.4	55.3	58.5
2	86.9	92.7	80.4	86.4	60.7	65.0	37.1	40.3			13.2	14.0	41.7	45.8
3	84.1	92.6	70.8	78.9	49.2	54.3	26.9	30.4			7.8	8.5	36.0	40.7
4	81.0	92.1	65.2	75.5	41.1	46.9	20.9	24.6			6.1	6.7	32.2	37.5
5	77.9	91.6	59.3	71.4	35.7	42.2	17.2	21.1			5.2	5.8	29.5	35.4
6	74.4	90.4	54.9	68.8	32.7	39.8	15.4	19.5			4.9	5.6	27.6	34.0
7	70.0	88.3	51.0	66.5	29.8	37.5	13.3	17.6			4.3	5.1	26.0	33.0
8	66.4	86.8	47.8	64.9	26.6	34.7	12.2	17.0			4.0	4.8	24.4	31.9
9	62.2	84.1	44.2	62.4	24.2	32.7	10.8	15.5			3.8	4.6	23.2	31.1
10	58.5	81.8	41.8	61.4	21.5	30.0	10.5	15.6			3.7	4.6	22.1	30.5
11	55.6	80.5	39.4	60.1	20.1	28.9	10.0	15.2			3.4	4.3	20.6	29.2
12	52.8	79.2	36.1	57.2	18.8	28.0	7.7	12.4			3.1	4.1	18.9	27.6
13	49.5	76.9	32.4	53.3	17.0	26.3	7.7	12.4					17.6	26.6
14	48.0	76.9	30.1	51.6	15.8	25.3							15.6	24.2
15	44.9	74.3	26.9	47.8	14.7	24.4							14.7	23.3

Table 4b. Observed (obs.) and relative (rel.) survival of patients with stomach cancer by UICC for period 1988-2016 (N=8,705).




Figure 4c. Relative survival of patients with stomach cancer by UICC. For 8,052 of 9,967 cases diagnosed between 1998 and 2016 valid data could be obtained for this item. For a total of 6,761 cases an evaluable classification was established. The grey line represents the subgroup of 3,206 patients with missing values regarding UICC (32.2 % of 9,967 patients, the percent values of all other categories are related to n=6,761).

Years	UICC											
	IA n=1,297		IB n=849		II n=1,110		IIIA n=696		IV n=2,809		NA/NOS n=3,206	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	90.0	93.0	87.4	90.7	78.1	80.8	61.9	64.6	32.7	33.9	54.9	58.1
2	86.3	92.1	81.3	87.4	61.8	66.1	39.7	43.1	13.8	14.6	41.2	45.1
3	83.5	92.2	72.3	80.7	49.9	54.9	29.0	32.8	8.1	8.8	35.2	39.8
4	80.3	91.6	66.3	77.0	41.8	47.6	22.9	27.0	6.2	6.8	31.3	36.4
5	76.5	90.5	59.9	72.2	36.6	43.0	18.9	23.3	5.2	5.9	28.7	34.3
6	73.9	90.6	55.7	70.0	33.1	40.2	16.2	20.5	5.0	5.7	26.8	33.0
7	69.3	88.3	51.3	67.3	30.1	37.8	14.1	18.7	4.6	5.4	25.4	32.1
8	65.8	87.2	47.7	65.3	26.9	34.9	13.3	18.3	4.2	5.0	24.0	31.2
9	61.6	84.7	43.2	61.5	24.0	32.3	10.4	15.0	4.0	4.9	23.0	30.6
10	56.8	81.3	40.3	60.0	21.2	29.3			4.0	4.9	21.7	29.7
11	53.2	78.9	38.3	59.1	20.4	29.1					20.0	28.2
12	50.2	77.4	34.5	55.5	19.7	29.0					18.3	26.6
13	47.8	77.0	31.9	52.7	18.1	27.9					16.0	24.0
14	46.5	77.8	30.7	52.6	16.8	26.8					13.0	19.8
15	44.8	77.4	27.0	49.4	16.1	26.6						

Table 4d. Observed (obs.) and relative (rel.) survival of patients with stomach cancer by UICC for period 1998-2016 (N=6,761).




Figure 4e. Relative survival of patients with stomach cancer by TNM staging. For 10,073 of 12,262 cases diagnosed between 1988 and 2016 valid data could be obtained for this item. For a total of 8,756 cases an evaluable classification was established. The accumulated percentage exceeds the 100 % value because patients are potentially considered in more than one subgroup. The grey line represents the subgroup of 3,506 patients with missing values regarding TNM staging (28.6 % of 12,262 patients, the percent values of all other categories are related to n=8,756).

Years	TNM staging													
	T1M0 n=1,590		T2M0 n=1,910		T3M0 n=1,622		T4M0 n=475		NOM0 n=2,435		N+M0 n=2,795		NXM0 n=204	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	91.0	93.7	82.5	85.4	73.9	76.3	65.5	67.7	89.7	92.6	73.6	76.0	85.0	87.7
2	86.7	92.0	69.1	73.9	54.0	57.4	41.8	44.3	83.4	88.8	53.2	56.6	79.4	84.8
3	83.0	90.8	58.1	64.2	44.0	48.0	29.9	32.6	77.5	85.2	41.9	45.7	74.5	82.4
4	80.1	90.4	51.1	58.4	37.5	42.2	24.9	27.5	73.5	83.4	34.8	39.0	70.3	81.0
5	76.6	89.2	45.8	54.2	33.4	38.6	22.2	25.2	69.6	81.6	30.1	34.8	62.4	72.8
6	72.7	87.3	42.2	51.7	30.4	36.0	19.3	22.5	65.3	79.1	27.7	32.9	60.4	74.2
7	69.0	85.8	38.9	49.5	27.6	33.6	18.5	22.3	61.2	76.9	25.6	31.3	60.4	75.8
8	65.6	84.4	35.7	47.1	25.2	31.7			57.6	74.8	23.5	29.7		
9	61.4	81.6	33.3	45.6	23.0	29.4			53.6	72.1	21.8	28.5		
10	58.5	80.3	30.9	43.8	21.7	28.6			51.2	71.1	20.1	27.0		
11	55.4	78.6	29.3	43.2	20.7	28.2			48.5	69.7	19.0	26.4		
12	52.9	77.6	27.2	41.5	18.3	25.8			45.7	68.1	17.4	24.9		
13	49.9	75.9	24.7	39.1	18.3	26.2			43.3	66.9	15.8	23.5		
14	48.2	75.9	22.5	36.9	16.2	23.9			41.5	66.3	14.2	21.8		
15	45.9	74.6	20.3	34.6	15.0	23.3			38.6	63.9	13.4	21.3		

<i>cont'd</i>	TNM staging			
	M1		NA/NOS	
	n=3,074		n=3,506	
Years	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	29.1	30.1	52.5	55.9
2	11.5	12.1	40.7	45.4
3	6.4	6.9	35.3	40.9
4	4.9	5.3	31.5	37.9
5	4.1	4.6	28.5	35.6
6	3.9	4.4	26.8	34.8
7	3.4	4.0	24.9	33.5
8	3.1	3.7	23.2	32.4
9	3.1	3.7	21.4	31.0
10	3.0	3.6	19.7	29.6
11	2.8	3.5	18.2	28.2
12			16.6	26.5
13			14.8	24.6
14			13.6	23.2
15			12.2	21.4

Table 4f. Observed (obs.) and relative (rel.) survival of patients with stomach cancer by TNM staging for period 1988-2016 (N=8,756).




Figure 4g. Relative survival of patients with stomach cancer by TNM staging. For 8,052 of 9,967 cases diagnosed between 1998 and 2016 valid data could be obtained for this item. For a total of 7,005 cases an evaluable classification was established. The accumulated percentage exceeds the 100 % value because patients are potentially considered in more than one subgroup. The grey line represents the subgroup of 2,962 patients with missing values regarding TNM staging (29.7 % of 9,967 patients, the percent values of all other categories are related to n=7,005).

Years	TNM staging													
	T1M0 n=1,257		T2M0 n=1,333		T3M0 n=1,347		T4M0 n=421		NOM0 n=1,858		N+M0 n=2,148		NXM0 n=187	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	90.6	93.4	82.8	85.7	76.3	78.7	68.1	70.4	89.8	92.7	74.9	77.3	86.1	88.5
2	86.1	91.5	70.7	75.4	57.8	61.3	44.3	46.9	84.0	89.5	54.9	58.1	82.0	87.0
3	82.7	90.7	59.5	65.5	47.7	51.8	31.8	34.6	78.3	86.1	43.3	47.1	77.4	84.9
4	79.7	90.2	52.5	59.9	41.0	45.9	26.8	29.4	74.3	84.5	35.8	40.0	72.6	82.7
5	75.7	88.6	47.1	55.6	36.9	42.3	24.0	27.0	70.1	82.4	31.1	35.7	65.0	74.2
6	72.5	87.8	43.3	53.1	33.4	39.1			66.4	80.7	28.2	33.3	62.4	74.8
7	68.6	86.1	40.0	50.8	30.5	36.6			62.2	78.4	26.1	31.6		
8	65.4	85.3	36.7	48.4	28.4	35.0			58.6	76.5	24.2	30.3		
9	61.4	82.9	33.7	46.1	25.5	32.1			54.4	73.7	22.2	28.6		
10	57.7	80.9	31.4	44.7	23.4	30.3			51.3	72.0	20.6	27.4		
11	53.7	78.2	30.3	44.5	23.4	30.6			48.7	70.8	19.6	26.7		
12	51.1	77.4	28.2	43.0	20.5	28.1			44.7	67.7	18.7	26.4		
13	48.4	76.8	26.5	41.5	20.5	28.0			43.0	67.7	17.1	25.0		
14	46.9	77.6	24.6	40.1					41.5	68.0	15.5	23.4		
15	45.6	78.1	22.8	38.7					39.8	67.4	14.8	23.1		

<i>cont'd</i>	TNM staging			
	M1		NA/NOS	
	n=2,581		n=2,962	
Years	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	30.5	31.5	50.8	54.2
2	11.9	12.6	38.9	43.5
3	6.6	7.1	33.5	39.0
4	4.9	5.3	29.8	36.1
5	4.1	4.6	26.9	33.7
6	4.0	4.5	25.4	33.1
7	3.6	4.1	23.5	31.8
8	3.2	3.8	21.9	30.8
9	3.2	3.8	20.0	29.1
10	3.2	3.8	17.9	27.1
11			16.6	25.8
12			15.2	24.6
13			13.2	22.2
14			11.6	19.7
15			10.0	17.8

Table 4h. Observed (obs.) and relative (rel.) survival of patients with stomach cancer by TNM staging for period 1998-2016 (N=7,005).




Figure 4i. Conditional relative 2-year survival of patients with stomach cancer by extent of disease. For 10,073 of 12,262 cases diagnosed between 1988 and 2016 valid data could be obtained for this item. For a total of 10,035 cases an evaluable classification was established. The grey line represents the subgroup of 2,227 patients with missing values regarding extent of disease (18.2 % of 12,262 patients, the percent values of all other categories are related to n=10,035).

Years	Extent of disease							
	Local		Regional		Distant		NA/NOS	
	n	Cond. surv. % 2 yrs	n	Cond. surv. % 2 yrs	n	Cond. surv. % 2 yrs	n	Cond. surv. % 2 yrs
0	3,457	85.1	3,504	54.5	3,074	12.1	2,227	36.6
1	2,784	91.7	2,335	59.9	844	22.9	901	72.7
2	2,396	94.0	1,606	69.4	300	44.2	662	86.3
3	2,079	95.8	1,183	75.9	153	67.0	549	91.4
4	1,815	96.3	913	83.7	103	83.3	479	94.5
5	1,568	96.0	718	90.2	82	85.9	411	96.6

Table 4j. Conditional relative 2-year survival of patients with stomach cancer by extent of disease for period 1988-2016 (N=10,035).

Conditional relative survival rates refer to the relative survival probability, in this case for 2 years after cancer diagnosis, compared to the age- and sex-matched population (=100 %) under the condition of being alive for a certain time period (x-axis in Figure 4g). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease="Local", who are alive at least 3 years after cancer diagnosis, the conditional relative 2-year survival rate is 95.8% (n=2,079).




Figure 5a. Time to first progression of 7,478 patients with stomach cancer diagnosed between 1998 and 2016 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

Years	Type of progression						
	Any type (CI)	Any type (1-KM)	Local relapse (CI)	Local relapse (1-KM)	Lymph node (CI)	Lymph node (1-KM)	Distant metastasis (CI)
	n=7,478 %	n=7,478 %	n=7,478 %	n=7,478 %	n=7,478 %	n=7,478 %	n=7,478 %
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1	31.5	32.9	2.2	2.9	0.5	0.6	15.3
2	42.0	44.5	4.0	5.7	0.8	1.1	22.7
3	47.0	50.1	5.1	7.8	1.1	1.6	26.3
4	49.8	53.5	5.9	9.4	1.2	2.0	28.5
5	51.4	55.4	6.3	10.3	1.3	2.1	29.9
6	52.4	56.6	6.5	10.7	1.3	2.2	30.6
7	53.0	57.5	6.7	11.4	1.4	2.3	31.0
8	53.5	58.2	6.9	11.7	1.4	2.3	31.2
9	54.2	59.3	7.1	12.4	1.4	2.3	31.7
10	54.6	59.9	7.2	12.8	1.4	2.5	32.0
11	54.8	60.2	7.3	13.1	1.4	2.5	32.1
12	55.0	60.5	7.4	13.5	1.4	2.5	32.3
13	55.2	60.9	7.4	13.5	1.4	2.5	32.4
14	55.3	61.2	7.5	13.8	1.4	2.5	32.5
15	55.6	61.7	7.5	13.8	1.4	2.5	32.6

<i>cont'd</i>	Type of progression		
	Distant metast. (1-KM)	NOS (CI)	NOS (1-KM)
	n=7,478 %	n=7,478 %	n=7,478 %
Years			
0	0.0	0.0	0.0
1	17.7	15.6	17.5
2	27.4	18.8	22.0
3	32.4	20.3	24.5
4	35.7	21.1	25.9
5	38.0	21.4	26.6
6	39.1	21.8	27.4
7	39.8	22.2	28.2
8	40.3	22.5	29.0
9	41.1	22.8	29.6
10	41.8	22.8	29.8
11	42.2	22.9	30.1
12	42.6	23.0	30.2
13	42.7	23.1	30.6
14	43.0	23.2	30.9
15	43.3	23.3	31.4

Table 5b. Time to first progression of patients with stomach cancer for period 1998-2016 (N=7,478).




Figure 5c. Observed post-progression survival of 3,975 patients with stomach cancer diagnosed between 1998 and 2016. These 3,975 patients with documented progression events during their course of disease represent 40.1 % of the totally 9,915 evaluated cases (incl. M1, n=2,437, 24.6 %). Patients with cancer relapse documented via death certificates only were excluded (n=2,161, 21.8 %). Multiple progression types on different sites are included in the evaluation even when not occurring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement “not specified” is the only information in registries regarding relapse of the disease. The category “Any type” denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100 % value because patients are potentially considered in more than one subgroup.

Years	Type of progression				
	Any type n=3,975 %	Local relapse n=555 %	Lymph node n=114 %	Distant metastasis n=3,415 %	NOS n=408 %
0	100.0	100.0	100.0	100.0	100.0
1	35.2	39.9	35.8	31.1	54.2
2	17.3	25.3		13.0	40.1
3	12.1	20.9		7.7	35.9
4	9.8	17.3		5.8	32.0
5	8.8	15.5		5.0	30.3
6	8.3	14.6		4.7	28.8
7	7.6			4.0	27.9
8	7.3			3.8	27.4
9	6.9			3.6	25.4
10	6.5			3.6	

Table 5d. Observed post-progression survival of patients with stomach cancer for period 1998-2016 (N=3,975).




Figure 5e. Observed post-progression (distant metastasis) survival of 4,143 patients with stomach cancer diagnosed between 1988 and 2016 by period of progression.

Years	Period of progression		
	1988-1997 n=646 %	1988-2006 n=1,519 %	2007+ n=1,978 %
0	100.0	100.0	100.0
1	21.1	26.8	34.7
2	8.7	10.5	15.3
3	5.0	6.1	9.2
4	4.3	4.7	6.8
5	3.6	4.0	6.0
6		3.7	5.8
7		3.1	5.4
8		2.8	
9		2.6	
10		2.6	

Table 5f. Observed post-progression (distant metastasis) survival of patients with stomach cancer for period 1988-2016 by period of progression (N=4,143).

Shortcuts

MCR Munich Cancer Registry, Germany

NCI National Cancer Institute, USA

SEER Surveillance, Epidemiology, and End Results, USA

UICC Union for International Cancer Control, Geneva

DCO Death certificate only Death certificate provides the only notification to the registry.

NA Not available

NOS Not otherwise specified

OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate)
Date of entry: diagnosis
Event: death from any cause

RS Relative survival Survival compared to “general population”,
ratio of observed to expected survival (Ederer II method),
reflecting cancer specific survival

AS Assembled survival Assembled chart of
observed, expected, relative survival

CS Conditional survival Survival probability under the condition of surviving
a given period of time

TTP Time to progression Time to first progression / relapse
Date of entry: diagnosis
Event: (progression / relapse): first local-, lymph node recurrence,
distant metastasis or unspecified progression

1-KM 1 minus Kaplan-Meier estimator
 (“inverse” Kaplan-Meier estimator)

CI Cumulative incidence
Death as competing risk (according to Kalbfleisch und Prentice)

PPS Post-progression survival Survival since first progression / relapse (Kaplan-Meier estimate)
Date of entry (progression / relapse): first local-, lymph node
recurrence, distant metastasis or unspecified progression
Event: death from any cause

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C16: Stomach cancer [Internet]. 2018 [updated 2018 Aug 22; cited 2018 Oct 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/surv/sC16__E-ICD-10-C16-Stomach-cancer-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.